Barclays PLC Mannkind Corp Transaction History

Barclays PLC

$854 Billion
Q3 2025

A detailed history of Barclays PLC transactions in Mannkind Corp stock. As of the latest transaction made, Barclays PLC holds 846,056 shares of MNKD stock, worth $4.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

846,056

Previous 1,081,245 21.75%

Holding current value

$4.28 Million

Previous $4.05 Million 12.31%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$3.42 - $5.74 $804,346 - $1.35 Million	-235,189 Reduced 21.75%	846,056 $4.54 Million
Q2 2025 Aug 13, 2025	BUY	$3.71 - $5.04 $2.35 Million - $3.19 Million	633,348 Added 141.4%	1,081,245 $4.05 Million
Q1 2025 May 15, 2025	SELL	$4.92 - $6.6 $512,890 - $688,023	-104,246 Reduced 18.88%	447,897 $2.25 Million
Q4 2024 Feb 13, 2025	BUY	$5.93 - $7.44 $191,408 - $240,148	32,278 Added 6.21%	552,143 $3.55 Million
Q3 2024 Nov 15, 2024	BUY	$5.01 - $6.7 $1.69 Million - $2.27 Million	338,121 Added 186.04%	519,865 $3.27 Million

Q2 2024 Aug 14, 2024	SELL	$4.05 - $5.43 $377,958 - $506,743	-93,323 Reduced 33.93%	181,744 $949,000
Q1 2024 May 15, 2024	SELL	$3.25 - $5.27 $1.42 Million - $2.3 Million	-435,845 Reduced 61.31%	275,067 $1.25 Million
Q4 2023 Feb 15, 2024	BUY	$3.34 - $4.29 $769,375 - $988,210	230,352 Added 47.93%	710,912 $2.59 Million
Q3 2023 Nov 07, 2023	SELL	$3.91 - $5.45 $533,597 - $743,761	-136,470 Reduced 22.12%	480,560 $1.98 Million
Q2 2023 Aug 03, 2023	BUY	$3.72 - $4.79 $216,440 - $278,696	58,183 Added 10.41%	617,030 $2.51 Million
Q1 2023 May 04, 2023	SELL	$3.95 - $5.63 $580,811 - $827,840	-147,041 Reduced 20.83%	558,847 $2.29 Million
Q4 2022 Feb 13, 2023	SELL	$3.02 - $5.37 $612,235 - $1.09 Million	-202,727 Reduced 22.31%	705,888 $3.72 Million
Q3 2022 Nov 03, 2022	BUY	$2.99 - $4.35 $2.66 Million - $3.88 Million	891,202 Added 5118.03%	908,615 $2.81 Million
Q2 2022 Aug 12, 2022	SELL	$2.67 - $4.77 $63,471 - $113,392	-23,772 Reduced 57.72%	17,413 $67,000
Q1 2022 May 16, 2022	SELL	$2.62 - $4.45 $677,332 - $1.15 Million	-258,524 Reduced 86.26%	41,185 $152,000
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $775,012 - $1.03 Million	191,361 Added 176.62%	299,709 $1.31 Million
Q3 2021 Nov 09, 2021	BUY	$3.89 - $5.48 $143,233 - $201,779	36,821 Added 51.48%	108,348 $471,000
Q2 2021 Aug 13, 2021	SELL	$3.61 - $5.45 $519,096 - $783,677	-143,794 Reduced 66.78%	71,527 $390,000
Q1 2021 May 13, 2021	BUY	$3.14 - $6.14 $440,899 - $862,141	140,414 Added 187.45%	215,321 $845,000
Q4 2020 Feb 11, 2021	SELL	$1.79 - $4.04 $51,185 - $115,523	-28,595 Reduced 27.63%	74,907 $235,000
Q3 2020 Nov 12, 2020	SELL	$1.56 - $2.08 $28,025 - $37,367	-17,965 Reduced 14.79%	103,502 $195,000
Q2 2020 Aug 12, 2020	BUY	$0.94 - $2.21 $21,037 - $49,459	22,380 Added 22.59%	121,467 $213,000
Q1 2020 May 13, 2020	SELL	$0.84 - $1.76 $96,436 - $202,056	-114,805 Reduced 53.67%	99,087 $102,000
Q4 2019 Feb 10, 2020	BUY	$1.14 - $1.49 $75,810 - $99,085	66,500 Added 45.12%	213,892 $276,000
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.44 $75,452 - $104,472	-72,550 Reduced 32.99%	147,392 $185,000
Q2 2019 Aug 14, 2019	SELL	$1.09 - $1.88 $8,100 - $13,972	-7,432 Reduced 3.27%	219,942 $253,000
Q1 2019 May 15, 2019	BUY	$1.14 - $2.25 $6,577 - $12,982	5,770 Added 2.6%	227,374 $448,000
Q3 2018 Nov 14, 2018	BUY	$1.01 - $2.19 $113,235 - $245,529	112,114 Added 102.4%	221,604 $405,000
Q2 2018 Aug 14, 2018	SELL	$1.59 - $2.38 $15,868 - $23,752	-9,980 Reduced 8.35%	109,490 $209,000
Q1 2018 May 15, 2018	SELL	$2.28 - $3.8 $158,843 - $264,738	-69,668 Reduced 36.83%	119,470 $272,000
Q4 2017 Feb 14, 2018	BUY	$2.28 - $6.71 $309,101 - $909,681	135,571 Added 253.09%	189,138 $439,000
Q3 2017 Nov 14, 2017	BUY	$1.15 - $2.29 $61,602 - $122,668	53,567	53,567 $116,000

Others Institutions Holding MNKD

# of Institutions

257

Shares Held

165M

Call Options Held

2.76M

Put Options Held

689K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.3B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account